Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
| ▸ | SRC | P12931 | 1/20 | 0.54 |
| ▸ | MMP1 | P03956 | 1/20 | 0.53 |
| ▸ | MMP7 | P09237 | 1/20 | 0.53 |
| ▸ | MMP9 | P14780 | 1/20 | 0.53 |
| ▸ | MMP8 | P22894 | 1/20 | 0.53 |
| ▸ | MMP13 | P45452 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | CNR1 | P21554 | 2/20 | 0.51 |
| ▸ | CNR2 | P34972 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2736550 | 0.87 | L3MBTL1 (0.60) | MEN1KMT2ANPC1RAB9AKDM4E | |
| SCHEMBL13991203 | 0.83 | CNR2 (0.65) | MEN1KMT2ACYP2C19ALDH1A1KDM4E | |
| SCHEMBL2736552 | 0.80 | MEN1 (0.61) | MEN1KMT2ANPC1RAB9ACYP2C19 | |
| SCHEMBL2736556 | 0.76 | CNR1 (0.70) | MEN1KMT2ANPC1RAB9ACYP2C19 | |
| SCHEMBL7201120 | 0.75 | MEN1 (1.00) | MEN1KMT2ANPC1RAB9AKDM4E | |
| SCHEMBL6381995 | 0.71 | TSHR (0.54) | MEN1KMT2ANPC1CYP2C19ALDH1A1 | |
| SCHEMBL5757403 | 0.71 | CNR1 (0.64) | MEN1KMT2ACYP2C19ALDH1A1KDM4E | |
| SCHEMBL13617372 | 0.71 | MEN1 (0.64) | MEN1KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL13591317 | 0.70 | BRD4 (0.67) | MEN1KMT2ARAB9ACYP2C19ALDH1A1 | |
| SCHEMBL2859054 | 0.69 | POLB (0.71) | MEN1KMT2ANPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088924-B2 | Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor | SHIONOGI & CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20100081686-A1 | Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter | TADA YUKIO | 2010-04-01 | — | — | US | disclosed |
| US-7652141-B2 | Immunosuppressants, analgesics, antiinflammatory agents | SHIONOGI & CO., LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
| US-20080312292-A1 | Antipruritics | YASUI KIYOSHI | 2008-12-18 | — | — | US | disclosed |
| US-20070027144-A1 | Novel use of cannabinoid receptor agonist | SHIONOGI & CO., LTD. (JP) | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027144-A1 | Novel use of cannabinoid receptor agonist | CNR2, CNR1, OPRM1 | MEN1 4737/4885KMT2A 2110/4885NPC1 3215/4885 |
| US-20100081686-A1 | Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter | CNR2, CNR1, NPY2R | MEN1 3159/4885KMT2A 2963/4885NPC1 4500/4885 |
| US-20080312292-A1 | Antipruritics | CNR1, CNR2, OPRL1 | MEN1 4507/4885KMT2A 2819/4885NPC1 2141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.